Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, multicenter, randomized, double blind, placebo controlled study of combination therapy for safety and efficacy in subjects with uncomplicated obesity

Next Previous
X
Search
Trial Profile

Phase 2, multicenter, randomized, double blind, placebo controlled study of combination therapy for safety and efficacy in subjects with uncomplicated obesity

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupropion (Primary) ; Naltrexone (Primary) ; Naltrexone/bupropion (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Sponsors Orexigen Therapeutics [CEASED]

    • Most Recent Events

    • 07 Dec 2010 Naltrexone/bupropion has received a positive recommendation from the FDA Advisory Committee for the treatment of obesity, as reported in an Orexigen Therapeutics and Takeda Pharmaceutical Company media release
    • 01 Dec 2009 Results published in the Journal of Clinical Endocrinology and Metabolism.
    • 01 Dec 2009 Primary endpoint 'Bodyweight reduction' has been met according to results published in the Journal of Clinical Endocrinology and Metabolism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top